Avenue Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Ed Arce initiated Avenue Therapeutics with a Buy rating and $11 price target, stating that its lead candidate, IV Tramadol, would be highly differentiated as the only IV opioid in the U.S. with a DEA Schedule IV if approved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.